Abstract mRNA-Lipid nanoparticles (LNPs) are at the forefront of global medical research.
With the development of mRNA-LNP vaccines to combat the COVID-19 pandemic, the …

Vaccination remains our main defence against influenza, which causes substantial annual
mortality and poses a serious pandemic threat. Influenza virus evades immunity by rapidly …

Here we report on the development and comprehensive evaluations of an mRNA vaccine for
chronic hepatitis B (CHB) treatment. In two different HBV carrier mouse models generated by …

Background The implementation of mRNA vaccines against COVID-19 has successfully
validated the safety and efficacy of the platform, while at the same time revealing the …

Codon optimization has evolved to enhance protein expression efficiency by exploiting the
genetic code's redundancy, allowing for multiple codon options for a single amino acid …

Influenza A viruses (IAVs) pose a significant global threat to human health. A tightly
controlled host immune response is critical to avoid any detrimental effects of IAV infection. It …

Influenza remains a public health threat, partly due to suboptimal effectiveness of vaccines.
One factor impacting vaccine effectiveness is strain mismatch, occurring when vaccines no …

Background Seasonal influenza remains a global public health concern. A messenger RNA
(mRNA)-based quadrivalent seasonal influenza vaccine, mRNA-1010, was investigated in a …

Currently, vaccination with influenza vaccines is still an effective strategy to prevent infection
by seasonal influenza virus in spite of some drawbacks with them. However, due to the rapid …

Influenza vaccines faced significant challenges in achieving sufficient protective efficacy and
production efficiency in the past. In recent decades, novel influenza vaccines, characterized …